FY2025 Earnings Estimate for LEXX Issued By Zacks Small Cap

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Small Cap dropped their FY2025 earnings per share (EPS) estimates for Lexaria Bioscience in a research report issued to clients and investors on Thursday, April 24th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.58) for the year, down from their previous forecast of ($0.57). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

Separately, HC Wainwright dropped their price objective on shares of Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, January 24th.

Lexaria Bioscience Price Performance

NASDAQ LEXX opened at $1.17 on Monday. The firm has a market capitalization of $20.54 million, a price-to-earnings ratio of -2.34 and a beta of 0.86. The company has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.92. Lexaria Bioscience has a 52-week low of $1.15 and a 52-week high of $4.44.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings data on Monday, April 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.14 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LEXX. Byrne Asset Management LLC lifted its holdings in shares of Lexaria Bioscience by 132.1% during the 4th quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock valued at $27,000 after buying an additional 7,400 shares during the last quarter. HighTower Advisors LLC grew its position in Lexaria Bioscience by 61.4% in the fourth quarter. HighTower Advisors LLC now owns 21,023 shares of the company’s stock worth $44,000 after acquiring an additional 8,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Lexaria Bioscience by 108.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,873 shares of the company’s stock worth $61,000 after purchasing an additional 15,050 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Lexaria Bioscience during the 4th quarter valued at $127,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lexaria Bioscience by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 166,679 shares of the company’s stock valued at $350,000 after purchasing an additional 16,288 shares during the last quarter. 13.06% of the stock is owned by institutional investors and hedge funds.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.